SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network (AVT) is experiencing heightened community interest, largely fueled by recent announcements including the incorporation of its DAO in the UAE and the strategic appointment of Dr. Marwan Al Zarouni to deepen its presence in the region. The community is actively discussing the potential for a significant breakout, emphasizing AVT's low market capitalization, robust Polkadot integration, and the expanding utility driven by its enterprise-focused Aventus Cloud offerings.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital deployment of its BlueBird 6 satellite, marking a pivotal step in its direct-to-device cellular broadband network vision. The community is buzzing with excitement over this technical milestone, seeing it as a derisking event that accelerates the "Space 5G" race. While many anticipate future launches and revenue growth, a contingent remains skeptical, highlighting the company's current valuation and the extended timeline to profitability.

TOSHI

TOSHI, known as the 'Face of Base,' is trending with its community actively 'buying the dip' amidst recent market volatility, sparking discussions around its resilience. Despite current price action, strong long-term conviction persists, fueled by anticipation of future catalysts like major exchange listings and the upcoming Toshi Mobile launch.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending after reports surfaced of an acquisition by a major pharmaceutical firm, which aims to bolster its vaccine pipeline with DVAX's hepatitis B vaccine, a developing shingles treatment, and a recently licensed oral vaccine program. The community is largely celebrating this strategic development, viewing it as a significant validation of Dynavax's assets and a definitive resolution to long-standing investor discussions.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending due to the Pipeline Hazardous Materials Safety Administration (PHMSA) granting approval for the Las Flores Pipeline restart, effectively shifting regulatory authority from California to federal oversight. This is seen by the community as a "game-changing" catalyst, de-risking the company's offshore oil assets and igniting speculation of a significant short squeeze and revaluation.

Avient Corp. engages in the business of thermoplastic compounds. It operates through the Color, Additives, and Inks and Specialty Engineered Materials segments. The Color, Additives, and Inks segment provides custom color and additive concentrates in solid and liquid form for thermoplastics, dispersions for thermosets, specialty inks, plasticols, and vinyl slush molding solutions. The Specialty Engineered Materials segment makes polymer formulations, services, and solutions for designers, assemblers, and processors of thermoplastic materials. The company was founded on August 31, 2000 and is headquartered in Avon Lake, OH.

Avient Corp

Avient (AVNT) is trending as the market reacts positively to recent strong financial performance and multiple analyst upgrades, underscoring the company's strategic shift toward organic growth in specialty materials. The community is actively discussing bullish technical signals, including significant volume and a 'coiled spring' pattern, with many anticipating further upside. This renewed interest is fueled by Avient's focus on innovative and sustainable solutions, positioning it favorably in evolving markets.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is drawing attention due to contrasting news, as its MS drug tolebrutinib faced regulatory delays and a Phase III trial setback, while its blockbuster Dupixent continues to secure new approvals and expanded indications globally. Amid these pipeline developments, the community is actively discussing Sanofi's strategic acquisitions, notably a major deal in immunology, alongside ongoing speculation about potential future targets in the dynamic biotech sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending on news of its upcoming inclusion in the S&P MidCap 400 index, driving significant community discussion around potential institutional buying and enhanced visibility. This development, coupled with its recent strong earnings report, first GAAP profit, and leadership in Agentic AI, fuels widespread bullish sentiment, with many anticipating substantial long-term growth and a potential short squeeze.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT is garnering significant attention following its recent listing on Robinhood and its deep integration as a prominent perp DEX within the Coinbase #Base platform, enabling high-leverage trading. The community is actively debating its potential to become a dominant player, viewing it as significantly undervalued compared to rivals like Aster and Hype, despite ongoing discussions around price volatility and tokenomics.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending after recently pausing its aggressive Bitcoin accumulation, instead raising significant cash reserves through share sales. This strategic shift has ignited intense community debate, with many questioning shareholder dilution and the stock's pronounced underperformance relative to Bitcoin, despite trading at a discount to its vast crypto holdings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncobiologics (NASDAQ:OTLK) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Ascendiant Capital Markets upped their target price on shares of Oncobiologics from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Monday...

Oncobiologics (NASDAQ:OTLK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oncobiologics from a "strong sell" rating to a "hold" rating in a research note on Saturday...

Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of +4.35% and -101.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Oncobiologics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Oncobiologics (NASDAQ:OTLK - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of...

Oncobiologics (OTLK) Expected to Announce Quarterly Earnings on Friday

Oncobiologics (NASDAQ:OTLK) will be releasing its Q4 2025 earnings before the market opens on Friday, December 26. (View Earnings Report at...

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Analysts

Shares of Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average rating of "Hold" by the six brokerages that are currently covering the stock, Marketbeat reports. One...

Oncobiologics (NASDAQ:OTLK) Stock Price Up 4.6% - Still a Buy?

Oncobiologics (NASDAQ:OTLK) Shares Up 4.6% - Time to Buy...

Oncobiologics (NASDAQ:OTLK) Trading Up 5.9% - Still a Buy?

Oncobiologics (NASDAQ:OTLK) Trading Up 5.9% - Should You Buy...

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

Outlook Therapeutics, Inc. (OTLK) announced on Thursday that the U.S. Food and Drug Administration (FDA) has declined to approve its investigational drug Lytenava for the treatment of wet age-related macular degeneration. Shares of the company nosedived by over 66% in Thursday’s pre-market session following the announcement.The agency cited a lack of substantial evidence of effectiveness as the basis for its decision. Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older. Wet age-related macular degeneration (wet AMD) is an advanced form of AMD where abnormal, leaky blood vessels grow under the retina, leading to rapid vision loss.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> trended within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.The agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/28/3140631/0/en/Outlook-Therapeutics-Provides-Regulatory-Update-on-U-S-Food-and-Drug-Administration-Review-of-ONS-5010-LYTENAVA-bevacizumab-vikg-for-the-Treatment-of-Wet-AMD.html">noted</a> in its letter to the company that the drug did not meet the primary efficacy endpoint in a study and recommended that confirmatory evidence of efficacy be submitted to support the application.CEO Bob Jahr said that the company is very disappointed with this outcome and intends to meet with the agency to receive additional clarity on requirements for approval.“It is important to also note that the CRL (letter) identified no other outstanding deficiencies in our BLA (application),” Jahr added.The company also said that it intends to continue its efforts to expand Lytenava into additional markets in Europe. It has already been granted Marketing Authorization by the European Commission in the European Union and Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.OTLK is up by 26% this year but down by 68% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lisa-cook-to-sue-trump-administration-firing-her-federal-reserve-board/chsH6GARdjs">Lisa Cook To Sue Trump Administration For Firing Her From Federal Reserve Board: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why

The US FDA declined to approve the firm’s investigational drug Lytenava for the treatment of wet age-related macular degeneration, citing a lack of substantial evidence of effectiveness.

Equity

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OTLK News

OTLKOutlook Therapeutics Inc